𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation—PROTECT

✍ Scribed by L. Fischer; J. Klempnauer; S. Beckebaum; H. J. Metselaar; P. Neuhaus; P. Schemmer; U. Settmacher; N. Heyne; P-A. Clavien; F. Muehlbacher; I. Morard; H. Wolters; W. Vogel; T. Becker; M. Sterneck; F. Lehner; C. Klein; G. Kazemier; A. Pascher; J. Schmidt; F. Rauchfuss; A. Schnitzbauer; S. Nadalin; M. Hack; S. Ladenburger; H. J. Schlitt

Book ID
114806429
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
900 KB
Volume
12
Category
Article
ISSN
1600-6135

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Conversion from a calcineurin inhibitor
Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial
✍ Paolo De Simone; Herold J. Metselaar; Lutz Fischer; Jérôme Dumortier; Karim Boud 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 220 KB

Calcineurin inhibitors (CNIs) contribute to renal dysfunction following liver transplantation. This prospective, randomized, multicenter, 6-month study (with an additional 6 months of follow-up) evaluated whether everolimus with CNI reduction or discontinuation would improve renal function in mainte

Improvement of renal function after the
Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction
✍ Javier F. Castroagudín; Esther Molina; Rafael Romero; Esteban Otero; Santiago To 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro

A randomized controlled trial of late co
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function
✍ Christopher J.E. Watson; Alexander E.S. Gimson; Graeme J. Alexander; Michael E.D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB 👁 1 views

Renal impairment is common in patients after liver transplantation and is attributable in large part to the use of calcineurin inhibitor (CNI)-based immunosuppression. We sought to determine whether conversion to sirolimus-based immunosuppression was associated with improved renal function. In a sin